TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21205556

Group type: EXPERIMENTAL
Intervention: Zinc in tablet form
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Zinc in suspension form
Number of subjects: 200

Group type: COMPARATOR
Intervention: WHO recommended treatment for diarrhoea
Number of subjects: 200
Study: 17395055

Group type: EXPERIMENTAL
Intervention: Cardiac contractility modulation (CCM) therapy; delivered continuously for 30 minutes in patients and 2 hours in dogs
Number of subjects: 15
Study: 16128874

Group type: EXPERIMENTAL
Intervention: Advice to drink 1.5 l of water per day
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 18
Study: 11870165

Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m² IV every 21 days
Number of subjects: 97

Group type: COMPARATOR
Intervention: Cyclophosphamide 500 mg/m², Doxorubicin 50 mg/m², and Cisplatin 50 mg/m² (CAP) IV every 21 days
Number of subjects: 97
Study: 10197659

Group type: EXPERIMENTAL
Intervention: Pump prime only aprotinin (280 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 8306012

Group type: EXPERIMENTAL
Intervention: Encainide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moricizine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3476058

Group type: EXPERIMENTAL
Intervention: Enteric coated aspirin 20 mg daily
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Enteric coated aspirin 40 mg daily
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Enteric coated aspirin 60 mg daily
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Enteric coated aspirin 60-80 mg daily
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Enteric coated aspirin greater than 100 mg daily
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Enteric coated aspirin 80 mg daily
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Enteric coated aspirin 100 mg daily
Number of subjects: 8
Study: 29764571

Group type: EXPERIMENTAL
Intervention: ECG localization and postoperative X‐ray localization
Number of subjects: 160

Group type: COMPARATOR
Intervention: Body surface measurement and postoperative X‐ray localization
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: ECG localization during PICC placement
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: ECG localization
Number of subjects: 160
Study: 27670795

Group type: EXPERIMENTAL
Intervention: Fast spin‐echo proton density‐weighted magnetic resonance imaging
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Baseline superficial femoral artery volumes
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: 2-year change in FV total volume
Number of subjects: 79
Study: 24697960

Group type: EXPERIMENTAL
Intervention: LED light with sodium perborate and distilled water
Number of subjects: 30

Group type: COMPARATOR
Intervention: Diode laser with sodium perborate and distilled water
Number of subjects: 30
Study: 22913409

Group type: EXPERIMENTAL
Intervention: Heat patch containing iron chip
Number of subjects: 147

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 147
Study: 20713439

Group type: EXPERIMENTAL
Intervention: Sensory transcutaneous electrical nerve stimulation (TENS) with therapeutic exercise
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo electrical stimulation with therapeutic exercise
Number of subjects: 36

Group type: COMPARATOR
Intervention: Exercise only
Number of subjects: 36
Study: 18589267

Group type: EXPERIMENTAL
Intervention: Modified harvesting technique of the semitendinosus (group A)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard harvesting technique (group B)
Number of subjects: 35
Study: 15859526

Group type: EXPERIMENTAL
Intervention: Pulsed short-wave diathermy (PSWD) with mean power of 18 W (thermal effect)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Pulsed short-wave diathermy (PSWD) with mean power of 1.8 W (athermal effect)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Sham short-wave diathermy treatment (control)
Number of subjects: 103
Study: 11801587

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B 3 mg/kg/day
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B 5 mg/kg/day
Number of subjects: 414

Group type: COMPARATOR
Intervention: Amphotericin B lipid complex (ABLC) 5 mg/kg/day
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B
Number of subjects: 414
Study: 10401542

Group type: EXPERIMENTAL
Intervention: Eight week rehabilitation programme combining group and individual therapies
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 67
Study: 8904255

Group type: EXPERIMENTAL
Intervention: Epidural sufentanil (50 mu g in 10 ml normal saline)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (10 ml normal saline)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Epidural sufentanil (50 mu g in 50 ml bupivacaine 0.125% at a rate of 6-10 ml/h)
Number of subjects: 40
Study: 1919423

Group type: EXPERIMENTAL
Intervention: Non-pharmacological treatment (NPT) programme
Number of subjects: 400

Group type: COMPARATOR
Intervention: Conventional drug treatment
Number of subjects: 400
Study: 7114615

Group type: EXPERIMENTAL
Intervention: Clindamycin plus gentamycin
Number of subjects: 64

Group type: COMPARATOR
Intervention: Cefoxitine alone
Number of subjects: 64
Study: 31471246

Group type: EXPERIMENTAL
Intervention: Blonanserin 40 mg
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Blonanserin 80 mg
Number of subjects: 580

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 580
Study: 30276562

Group type: EXPERIMENTAL
Intervention: Higher neuroticism
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Higher conscientiousness and extraversion
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Neuroticism
Number of subjects: 92
Study: 30115212

Group type: EXPERIMENTAL
Intervention: Management of children and adolescents with suicidal ideation or behaviour
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Willingness to prescribe antidepressants
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Difficulty in managing this patient group
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Access to services
Number of subjects: 198
Study: 26273146

Group type: EXPERIMENTAL
Intervention: I-gel facilitated endotracheal tube intubation (Group TI)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Tracheal tube intubation (Group TT)
Number of subjects: 66
Study: 24589724

Group type: EXPERIMENTAL
Intervention: CKD273 urinary proteome-based classifier
Number of subjects: 165
Study: 22525775

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Combined Treatment (AT/RT)
Number of subjects: 117
Study: 19788364

Group type: EXPERIMENTAL
Intervention: Vaginal estrogen therapy (creams, tablets, rings)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systemic estrogen therapy
Number of subjects: 0
Study: 17971946

Group type: EXPERIMENTAL
Intervention: BCG-PSN injection plus inhaled glucocortisteriods
Number of subjects: 37

Group type: COMPARATOR
Intervention: Inhaled glucocortisteriods only
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 37
Study: 15455619

Group type: EXPERIMENTAL
Intervention: ICT-TB test in pulmonary TB smear positive patients
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: ICT-TB test in pulmonary TB smear negative patients
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: ICT-TB test in patients with TB pleural effusion
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: ICT-TB test in patients with TB lymphadenitis
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (non-TB patients and healthy subjects)
Number of subjects: 129
Study: 11447080

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 9586317

Group type: EXPERIMENTAL
Intervention: Propoleum
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study: 10548622

Group type: EXPERIMENTAL
Intervention: 10 ml of 1.5% lignocaine (group A)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Normal saline (group B)
Number of subjects: 135

Group type: COMPARATOR
Intervention: No local injection (group C)
Number of subjects: 135
Study: 2269086

Group type: EXPERIMENTAL
Intervention: Prophylaxis programme for small groups including tooth cleaning, professional plaque removal, and local fluoridation.
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 190
Study: 424490

Group type: EXPERIMENTAL
Intervention: Psychological assessment before management regimes
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Psychological assessment
Number of subjects: 83

Group type: COMPARATOR
Intervention: Physiological tests of lung functioning, exercise tolerance test, reported symptoms, time off work, drop-out, and death
Number of subjects: 83
Study: 31607677

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day plus rifaximin 1200 mg/day
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day plus rifaximin 1200 mg/day
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 29987559

Group type: EXPERIMENTAL
Intervention: REThink intervention (N=54)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Rational Emotive Behavior Education group (N=55)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Waitlist condition (N=56)
Number of subjects: 165
Study: 28028552

Group type: EXPERIMENTAL
Intervention: Mechanical prophylaxis (MP)
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Pharmacological prophylaxis
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: VTE development
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Patient weight
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: TBI severity
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: VTE development and mortality
Number of subjects: 603
Study: 25882778

Group type: EXPERIMENTAL
Intervention: Tetracycline 250 mg every 12h for 4 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (no tetracycline)
Number of subjects: 90
Study: 23527502

Group type: EXPERIMENTAL
Intervention: Subjectively pleasant activities
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Higher levels of depression
Number of subjects: 41
Study: 22126919

Group type: EXPERIMENTAL
Intervention: Cemented hemiarthroplasty
Number of subjects: 22

Group type: COMPARATOR
Intervention: Uncemented hemiarthroplasty
Number of subjects: 22
Study: 19398277

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (35 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 17362946

Group type: EXPERIMENTAL
Intervention: 30 minutes of bed rest after embryo transfer
Number of subjects: 164

Group type: COMPARATOR
Intervention: Immediate discharge from the clinic
Number of subjects: 164
Study: 15470487

Group type: EXPERIMENTAL
Intervention: AB killer cell immunoglobulin-like receptor (KIR) phenotype in leukemic patients
Number of subjects: 244

Group type: COMPARATOR
Intervention: AB killer cell immunoglobulin-like receptor (KIR) phenotype in healthy controls
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Inhibitory KIR2DL2 in leukemic patients
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: KIR phenotypes AB1 and AB9
Number of subjects: 244
Study: 11467911

Group type: EXPERIMENTAL
Intervention: Scopolamine (intravenous injection)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Glycopyrrolate (intravenous injection)
Number of subjects: 13
Study: 9601623

Group type: EXPERIMENTAL
Intervention: Ketoprofen 25 mg
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg
Number of subjects: 457

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 457
Study: 7976460

Group type: EXPERIMENTAL
Intervention: Treatment program (details not specified)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cognitive test battery (backward masking)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Communication Conflict Situation and Camberwell Family Interview (for parents)
Number of subjects: 11
Study: 3371882

Group type: EXPERIMENTAL
Intervention: Intravenous hypertonic glucose (900 mOsmoles per liter) at 2 ml per min
Number of subjects: 16

Group type: COMPARATOR
Intervention: Mannitol (n = 4)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline (n = 4)
Number of subjects: 16
Study: 31863865

Group type: EXPERIMENTAL
Intervention: Tofacitinib ECS tablets (11 mg and 22 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5 mg immediate-release formulation tablet
Number of subjects: 0
Study: 30181096

Group type: EXPERIMENTAL
Intervention: Nemonoxacin 500 mg once daily for 7-10 days
Number of subjects: 527

Group type: COMPARATOR
Intervention: Levofloxacin 500 mg once daily for 7-10 days
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Nemonoxacin
Number of subjects: 527

Group type: COMPARATOR
Intervention: Levofloxacin
Number of subjects: 527
Study: 27389435

Group type: EXPERIMENTAL
Intervention: Short-6 mm implant
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Short-8 mm implant with OSFE
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Standard-10 mm implant with OSFE
Number of subjects: 56
Study: 26354859

Group type: EXPERIMENTAL
Intervention: SPEACS communication strategies
Number of subjects: 1440
Study: 25445508

Group type: EXPERIMENTAL
Intervention: Too Good for Drugs (TGFD) prevention program
Number of subjects: 10762

Group type: COMPARATOR
Intervention: Control group (6th graders not participating in TGFD)
Number of subjects: 10762
Study: 20686007

Group type: EXPERIMENTAL
Intervention: Provider origin bacterial transmission to the IV stopcock set
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Provider origin bacterial transmission to the anesthesia environment
Number of subjects: 164

Group type: COMPARATOR
Intervention: Independent predictors of bacterial transmission events
Number of subjects: 164
Study: 19244691

Group type: EXPERIMENTAL
Intervention: Antegrade cannulation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Retrograde cannulation
Number of subjects: 120
Study: 16776793

Group type: EXPERIMENTAL
Intervention: Age-specific computerized prescribing alerts
Number of subjects: 50924

Group type: EXPERIMENTAL
Intervention: Group academic detailing
Number of subjects: 50924

Group type: COMPARATOR
Intervention: Drug-specific computerized prescribing alerts (baseline)
Number of subjects: 50924
Study: 14687170

Group type: EXPERIMENTAL
Intervention: OAF (Omeprazole 20 mg b.d., Amoxicillin 1000 mg b.d., Furazolidone 100 mg b.d. for 14 days)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: OABF1 (Omeprazole 20 mg b.d., Amoxicillin 1000 mg b.d., Furazolidone 100 mg b.d., Bismuth Subcitrate 240 mg b.d. for 14 days)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: OABF2 (Omeprazole 20 mg b.d., Amoxicillin 1000 mg b.d., Furazolidone 200 mg b.d., Bismuth Subcitrate 240 mg b.d. for 14 days)
Number of subjects: 150
Study: 11374675

Group type: EXPERIMENTAL
Intervention: Eradication therapy
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Long-term omeprazole therapy
Number of subjects: 276
Study: 9291702

Group type: EXPERIMENTAL
Intervention: Subcutaneous morphine administration
Number of subjects: 36

Group type: COMPARATOR
Intervention: Oral morphine administration
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Patients with elevated serum creatinine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Patients with normal serum creatinine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Patients with opioid-induced adverse effects
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Patients with elevated plasma M3G and M6G concentrations
Number of subjects: 36
Study: 8404995

Group type: EXPERIMENTAL
Intervention: Sodium lactate infusion at rates of 6 to 40 mumol kg‐1 min‐1
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sodium bicarbonate infusion (control)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Overall rates of lactate appearance during lactate infusions
Number of subjects: 17
Study: 3951079

Group type: EXPERIMENTAL
Intervention: Confidential feedback on individual rates of use compared with peers (cost feedback)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feedback on rates of abnormal test results (yield feedback)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Test-specific education
Number of subjects: 0
Study: 29369240

Group type: EXPERIMENTAL
Intervention: CapsoCam SV‐1
Number of subjects: 153

Group type: COMPARATOR
Intervention: PillCam SB 3
Number of subjects: 153
Study: 29779815

Group type: EXPERIMENTAL
Intervention: Enteral formula with prebiotic content (EFPC)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard enteral formula (SEF)
Number of subjects: 46
Study: 27348913

Group type: EXPERIMENTAL
Intervention: Acupuncture at the acupoints selected from the affected meridians and heavy moxibustion at painful points, applied once every two days, three times a week, for 4 weeks.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Medication group with tramadol sustained release tablets and amitriptyline, prescribed once a day for 4 weeks.
Number of subjects: 32
Study: 25059532

Group type: EXPERIMENTAL
Intervention: Guanfacine (1mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 22687580

Group type: EXPERIMENTAL
Intervention: SAMe 800-1600 mg/d for 6 weeks
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: SAMe
Number of subjects: 73
Study: 21179684

Group type: EXPERIMENTAL
Intervention: Maltitol chewing gums
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Xylitol chewing gums
Number of subjects: 30

Group type: COMPARATOR
Intervention: Gum base chewing gums
Number of subjects: 30
Study: 18096050

Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control intervention (placement of local anesthesia near the fracture)
Number of subjects: 166
Study: 15764352

Group type: EXPERIMENTAL
Intervention: Legs covered with towels during DHT (24 treatments)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Legs not covered with towels during DHT (27 treatments)
Number of subjects: 14
Study: 12062853

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 51

Group type: COMPARATOR
Intervention: Withdrawal of metformin
Number of subjects: 51
Study: 9458021

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1.5 g twice daily with intravenous corticosteroids (5 mg/kg/day for 5 days followed by oral taper)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Azathioprine (AZA) 1-2 mg/kg/day with intravenous corticosteroids (5 mg/kg/day for 5 days followed by oral taper)
Number of subjects: 221
Study: 8574509

Group type: EXPERIMENTAL
Intervention: 400 mg of hymecromone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2676941

Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanate potassium (Augmentin)
Number of subjects: 40
Study: 80577

Group type: EXPERIMENTAL
Intervention: Ultraviolet irradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Background irradiation
Number of subjects: 0
Study: 31959263

Group type: EXPERIMENTAL
Intervention: Genetic risk score based on four of the six SNP associated with low 25(OH)D
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: VDR SNP
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Genetic risk score
Number of subjects: 699
Study: 30777024

Group type: EXPERIMENTAL
Intervention: HBV-DNA-positive group
Number of subjects: 0

Group type: COMPARATOR
Intervention: HBV-DNA-negative group
Number of subjects: 0
Study: 29351537

Group type: EXPERIMENTAL
Intervention: Enhanced recovery regime (no Redon drain, intensified analgesia, immediate mobilization)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Conventional regime (with Redon drain, no femoral nerve block, no immediate mobilization)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Both groups (Enhanced and Conventional)
Number of subjects: 194
Study: 25422883

Group type: EXPERIMENTAL
Intervention: CP-601,927 2 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23312429

Group type: EXPERIMENTAL
Intervention: Naltrexone with MBSCT and enhanced medication management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo with MBSCT and enhanced medication management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naltrexone with enhanced medication management only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with enhanced medication management only
Number of subjects: 0
Study: 20716475

Group type: EXPERIMENTAL
Intervention: Needle Aspiration (NA)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Minichest Tube (MCT)
Number of subjects: 48
Study: 19272057

Group type: EXPERIMENTAL
Intervention: Quinidine therapy
Number of subjects: 9
Study: 16732777

Group type: EXPERIMENTAL
Intervention: Breastfeeding counseling by trained midwives and nurses
Number of subjects: 540
Study: 15306152

Group type: EXPERIMENTAL
Intervention: Monoclonal antiphospholipid antibodies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human sera containing antiphospholipid antibodies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Resting endothelial cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Activated endothelial cells
Number of subjects: 0
Study: 11170325

Group type: EXPERIMENTAL
Intervention: Right radial approach
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Left radial approach
Number of subjects: 210

Group type: COMPARATOR
Intervention: Femoral approach
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Both radial approaches
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Transradial approach
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 210
Study: 9421239

Group type: EXPERIMENTAL
Intervention: Intermittent slow‐release sodium fluoride (SRNaF) and continuous calcium citrate
Number of subjects: 33
Study: 8431313

Group type: EXPERIMENTAL
Intervention: i.v. morphine
Number of subjects: 32

Group type: COMPARATOR
Intervention: extradural bupivacaine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: both techniques
Number of subjects: 32